Author(s): Ana Murtasyidah, Betty Agustina Tambunan, Mia Ratwita Andarsini

Email(s): murtasyidah@gmail.com

DOI: 10.52711/0974-360X.2021.00743   

Address: Ana Murtasyidah1*, Betty Agustina Tambunan2, Mia Ratwita Andarsini3
1Clinical Pathology Specialization Program, Faculty of Medicine, Airlangga University, Dr. Soetomo Hospital, Surabaya, Indonesia.
2Department of Clinical Pathology, Faculty of Medicine, Airlangga University, Dr. Soetomo Hospital, Surabaya Indonesia.
3Department of Pediatrics, Faculty of Medicine, Airlangga University, Dr. Soetomo Hospital, Surabaya Indonesia.
*Corresponding Author

Published In:   Volume - 14,      Issue - 8,     Year - 2021


ABSTRACT:
Platelet transfusion is being used in 67%-75% of hematology malignancies including leukemia. Platelet refractoriness is the failure to achieve satisfactory responses to platelet transfusions. Many transfusion centres use 1 hour and 24 hours after transfusion Corrected Count Increment (CCI) value to define platelet refractoriness. To analyze platelet refractory based on CCI-1h and CCI-24h value after Platelet Concentrate (PC) tranfusion in pediatric leukemia and the effect of non immune factors on platelet refractoriness. Subjects were evaluated for platelet count after 10-120 minutes and 18-24 hours of PC tranfusion to calculate CCI-1h and CCI-24h. Platelet Refractoriness was defined when CCI-1h <5×109/L and CCI-24h <4.5×109/L. Each subject was observed for non-immune platelet refractory factors. Interestingly, from 25 PC transfusion there was 20% platelet refractoriness of CCI-1h and 40% of CCI-24h. There was a significant difference CCI-1h and CCI-24h (p=0.027). Non immune factor had no effect for platelet refractoriness. Platelet count should be analyzed after 24 hours PC transfusion to diagnose platelet refractoriness. Further research including immune factor examination is needed.


Cite this article:
Ana Murtasyidah, Betty Agustina Tambunan, Mia Ratwita Andarsini. Platelet Refractoriness Evaluation after Platelet Concentrate Transfusion in Pediatric Leukemia. Research Journal of Pharmacy and Technology. 2021; 14(8):4277-0. doi: 10.52711/0974-360X.2021.00743

Cite(Electronic):
Ana Murtasyidah, Betty Agustina Tambunan, Mia Ratwita Andarsini. Platelet Refractoriness Evaluation after Platelet Concentrate Transfusion in Pediatric Leukemia. Research Journal of Pharmacy and Technology. 2021; 14(8):4277-0. doi: 10.52711/0974-360X.2021.00743   Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-8-49


REFERENCES:
1.    Liebman HA. Thrombocytopenia in cancer patients. Thromb. Res. 2014; 133: S63-S69.
2.    Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: A clinical practice guideline from the AABB. Ann Intern Med. 2015; 162(3): 205-213.
3.    Wandt H, Schäfer-Eckart K, Greinacher A. Platelet transfusion in hematology, oncology and surgery. Dtsch Arztebl Int. 2014; 111(48): 809-815.
4.    Crighton GL, Estcourt LJ, Wood EM, et al. Platelet transfusions in patients with hypoproliferative thrombocytopenia: Conclusions from clinical trials and current controversies. Hematol Oncol Clin North Am. 2016; 30(3): 541-60.
5.    Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. British Journal of Haematology. 2017; 176(3): 365.
6.    Murphy MF. Managing the platelet refractory patient. ISBT Sci Ser. 2014; 9: 234-238.
7.    Stanworth SJ, Navarrete C, Estcourt L, et al. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015; 171(3): 297-305.
8.    Kerkhoffs JL, Eikenboom JC, van de Watering LM, et al. The clinical impact of platelet refractoriness: Correlation with bleeding and survival. Transfusion. 2008; 48(9): 1959-1965.
9.    Castillo B, Dasgupta A, Klein K, et al. Transfusion Medicine for Pathologists: A Comprehensive Review for Board Preparation, Certification, and Clinical Practice 1st Ed. USA: Elsevier; 2018.
10.    Thuku NW, Shikuku K, Mbugua A. Determination in vivo viability of a transfused platelet product by corrected count increment and percentage platelet response. Pan Afr Med J. 2017; 27: 226.
11.    Slichter SJ, Grabowski M. Townsend-McCall. et al. Prospective randomized transfusion trial to directly compare fresh and stored apheresis platelets (AP) and pooled random donor platelet concentrates (PC) in thrombocytopenic patients. Blood. 1998; 92: 2771A.
12.    Forest SK, Hod EA. Management of the platelet refractory patient. Hematol Oncol Clin N. 2016; 30: 665-677.
13.    Weiss ED, Mintz PD. Platelet refractorines and alloimunization. Transfus Med Rev. 2000; 14(2): 180-196.
14.    Abraham AS, Chacko MP, Fouzia NA, et al. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions. Transfus Med. 2018; 28(5): 392-397.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available